DCI Partners

DCI Partners is a subsidiary of Daiwa Corporate Investment, part of the Daiwa Securities Group investment network. The firm invests in unlisted biotechnology startups, with a focus on drug discovery and regenerative medicine, across Japan and Taiwan. Its investment activity is concentrated at the business-development stage of drug development ventures.

The firm operates a biotech investment fund described as among the largest raised in Japan, though no figure has been disclosed. The fund's stated purpose is to address a financing gap facing drug discovery and regenerative medicine ventures at the business-development stage - a point in the development pipeline where capital for advancing candidate medicines is often insufficient. DCI Partners combines specialist biotechnology investment capability with the broader venture capital and fund management experience of the Daiwa Securities Group.

Beyond backing existing companies, DCI Partners also forms new startups through fund-led projects, extending its role from investor to company builder. Investment activity spans biotechnology, pharmaceuticals and drug discovery, and regenerative medicine, alongside the firm's fund management function. DCI Partners does not disclose founding year, team size, or check size parameters publicly.